Literature DB >> 26021286

Targeting microRNAs for immunomodulation.

Lukas T Jeker1, Romina Marone2.   

Abstract

microRNAs (miRNA) are small regulatory RNAs exerting pleiotropic functions in virtually any immune cell-type. Dozens of miRNAs with a known function in the immune system constitute interesting drug targets for immunomodulation. Chemical modifications of nucleic acid-based miRNA mimics and inhibitors largely solved instability issues but delivery to immune cells remains a major challenge. However, recent success targeting the acidic tumor microenvironment is very promising for inflammatory diseases. Moreover, small molecules are being explored as an interesting alternative. Although RNA is often considered 'undruggable' by small molecules recent progress modulating miRNA function through small molecules is encouraging. Computational approaches even allow predictions about specific small molecule/RNA interactions. Finally, recent clinical success demonstrates that drugs targeting RNAs work in humans.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26021286      PMCID: PMC4516684          DOI: 10.1016/j.coph.2015.05.004

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  53 in total

1.  miR-155 promotes T follicular helper cell accumulation during chronic, low-grade inflammation.

Authors:  Ruozhen Hu; Dominique A Kagele; Thomas B Huffaker; Marah C Runtsch; Margaret Alexander; Jin Liu; Erin Bake; Wei Su; Matthew A Williams; Dinesh S Rao; Thomas Möller; Gwenn A Garden; June L Round; Ryan M O'Connell
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

Review 2.  What makes a good drug target?

Authors:  Isabella Gashaw; Peter Ellinghaus; Anette Sommer; Khusru Asadullah
Journal:  Drug Discov Today       Date:  2011-09-16       Impact factor: 7.851

Review 3.  MicroRNAs in stress signaling and human disease.

Authors:  Joshua T Mendell; Eric N Olson
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

4.  A microRNA polycistron as a potential human oncogene.

Authors:  Lin He; J Michael Thomson; Michael T Hemann; Eva Hernando-Monge; David Mu; Summer Goodson; Scott Powers; Carlos Cordon-Cardo; Scott W Lowe; Gregory J Hannon; Scott M Hammond
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

Review 5.  The biological functions of miRNAs: lessons from in vivo studies.

Authors:  Joana A Vidigal; Andrea Ventura
Journal:  Trends Cell Biol       Date:  2014-12-04       Impact factor: 20.808

6.  Targeting miR-21 to treat psoriasis.

Authors:  Juan Guinea-Viniegra; María Jiménez; Helia B Schonthaler; Raquel Navarro; Yolanda Delgado; María José Concha-Garzón; Erwin Tschachler; Susanna Obad; Esteban Daudén; Erwin F Wagner
Journal:  Sci Transl Med       Date:  2014-02-26       Impact factor: 17.956

7.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

Authors:  Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

8.  Short loop-targeting oligoribonucleotides antagonize Lin28 and enable pre-let-7 processing and suppression of cell growth in let-7-deficient cancer cells.

Authors:  Martina Roos; Mario A E Rebhan; Matije Lucic; David Pavlicek; Ugo Pradere; Harry Towbin; Gianluca Civenni; Carlo V Catapano; Jonathan Hall
Journal:  Nucleic Acids Res       Date:  2014-11-06       Impact factor: 16.971

9.  The Business of RNAi Therapeutics in 2012.

Authors:  Dirk Haussecker
Journal:  Mol Ther Nucleic Acids       Date:  2012-02-07       Impact factor: 10.183

10.  A component of the mir-17-92 polycistronic oncomir promotes oncogene-dependent apoptosis.

Authors:  Virginie Olive; Erich Sabio; Margaux J Bennett; Caitlin S De Jong; Anne Biton; James C McGann; Samantha K Greaney; Nicole M Sodir; Alicia Y Zhou; Asha Balakrishnan; Mona Foth; Micah A Luftig; Andrei Goga; Terence P Speed; Zhenyu Xuan; Gerard I Evan; Ying Wan; Alex C Minella; Lin He
Journal:  Elife       Date:  2013-10-15       Impact factor: 8.140

View more
  5 in total

1.  MicroRNA expression profiles in human CD3+ T cells following stimulation with anti-human CD3 antibodies.

Authors:  Isabel Garcia Sousa; Manuela Maragno do Almo; Kelly Cristina Rodrigues Simi; Maryani Andressa Gomes Bezerra; Rosângela Vieira Andrade; Andréa Queiroz Maranhão; Marcelo Macedo Brigido
Journal:  BMC Res Notes       Date:  2017-03-14

Review 2.  Biomarkers of Neurodegeneration and Precision Therapy in Retinal Disease.

Authors:  Alessandra Micera; Bijorn Omar Balzamino; Antonio Di Zazzo; Lucia Dinice; Stefano Bonini; Marco Coassin
Journal:  Front Pharmacol       Date:  2021-01-18       Impact factor: 5.810

Review 3.  Emerging Role and Therapeutic Implication of Wnt Signaling Pathways in Autoimmune Diseases.

Authors:  Juan Shi; Shuhong Chi; Jing Xue; Jiali Yang; Feng Li; Xiaoming Liu
Journal:  J Immunol Res       Date:  2016-03-27       Impact factor: 4.818

4.  Acupuncture Decreases NF-κB p65, miR-155, and miR-21 and Increases miR-146a Expression in Chronic Atrophic Gastritis Rats.

Authors:  Jialing Zhang; Kangbai Huang; Guoxin Zhong; Yong Huang; Suhe Li; Shanshan Qu; Jiping Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2016-05-18       Impact factor: 2.629

5.  Cobalt Chloride Enhances the Anti-Inflammatory Potency of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells through the ERK-HIF-1α-MicroRNA-146a-Mediated Signaling Pathway.

Authors:  Jihye Kwak; Soo Jin Choi; Wonil Oh; Yoon Sun Yang; Hong Bae Jeon; Eun Su Jeon
Journal:  Stem Cells Int       Date:  2018-09-05       Impact factor: 5.443

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.